Budesonide Nebulization
Approved
Budesonide Nebulization is one of 20 therapeutic programs targeting Wheezing. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
26 competitors in Wheezing
#DrugCompanyPhaseTrials
1Flovent
GSKApproved
Spiriva
Boehringer IngelheimApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Deltavit
HHyundai Pharmaceutical Co., LTD.
Approved
Salbutamol
GSKApproved
Qvar
Chiesi Farmaceutici S.p.A.Phase 3
Pulmicort
SSalix
Phase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Prednisolone Sodium Phosphate
UUniversity of Oulu
Approved
Nebulized Budesonide
DDeborah Gentile
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Wheezing1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Budesonide Nebulization. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Approved[1]